PD-1 (Human) sgRNA-MS2 Lentivirus (Integrating)

DESCRIPTION

The binding of Programmed Cell Death Protein 1 (PD-1), a receptor expressed on activated T-cells, to its ligands PD-L1 and PD-L2, negatively regulates immune responses. PD-1 ligands are found on most cancers, and the PD-1:PD-L1/2 interaction inhibits T-cell activity and enables cancer cells to escape immune surveillance. The PD-1:PD-L1/2 pathway is also involved in regulating autoimmune responses, making these proteins promising therapeutic targets for a number of cancers, as well as multiple sclerosis, arthritis, lupus, and type I diabetes. The PD-1 sgRNA-MS2 Lentiviruses are replication incompetent, HIV-based VSV-G pseudotyped lentiviral particles that are ready to infect almost all types of mammalian cells, including primary and non-dividing cells. The particles contain 5 sgRNA-MS2 (single guide RNA fused with an MS2 tag). When transduced in cells expressing dCas9-VP64 and MS2-P65-HSF1, these other proteins are recruited to the site in the genomic DNA that is targeted by the sgRNA and begin transcription, inducing expression of PD-1.

DETAILS

Notes: The CRISPR/CAS9 technology is covered under numerous patents, including U.S. Patent Nos. 8,697,359 and 8,771,945, as well as corresponding foreign patents applications, and patent rights. License Disclosure: Visit bpsbioscience.com/license for the label license and other key information about this product. Troubleshooting Guide: Visit bpsbioscience.com/lentivirus-faq for detailed troubleshooting instructions. For all further questions, please email support@bpsbioscience.com.
Species: Replication Incompetent HIV
Shiptemp: -80°C (dry ice)
Warnings: Avoid repeated freeze-thaw cycles. Titers can drop significantly with each freeze-thaw cycle. Biosafety None of the HIV genes (gag, pol, rev) will be expressed in the transduced cells. Although the pseudotyped lentiviruses are replication-incompetent, they require the use of a Biosafety Level 2 facility. BPS recommends following all local federal, state, and institutional regulations and using all appropriate safety precautions.
Category: Immunotherapy/Lentivirus
Description: The binding of Programmed Cell Death Protein 1 (PD-1), a receptor expressed on activated T-cells, to its ligands PD-L1 and PD-L2, negatively regulates immune responses. PD-1 ligands are found on most cancers, and the PD-1:PD-L1/2 interaction inhibits T-cell activity and enables cancer cells to escape immune surveillance. The PD-1:PD-L1/2 pathway is also involved in regulating autoimmune responses, making these proteins promising therapeutic targets for a number of cancers, as well as multiple sclerosis, arthritis, lupus, and type I diabetes. The PD-1 sgRNA-MS2 Lentiviruses are replication incompetent, HIV-based VSV-G pseudotyped lentiviral particles that are ready to infect almost all types of mammalian cells, including primary and non-dividing cells. The particles contain 5 sgRNA-MS2 (single guide RNA fused with an MS2 tag). When transduced in cells expressing dCas9-VP64 and MS2-P65-HSF1, these other proteins are recruited to the site in the genomic DNA that is targeted by the sgRNA and begin transcription, inducing expression of PD-1.
Formulation: The lentiviruses were produced from HEK293T cells in medium containing 90% DMEM + 10% FBS.
Supplied As: Two vials (500 µl x 2) of lentivirus at a titer ≥1 x 106 TU/ml. The titer will vary with each lot; the exact value is provided with each shipment.
Unspsc Code: 41106621
Unspsc Name: Virus mediated expression vectors or kits
Product Type: Lentivirus
Biosafety Level: BSL-2
Related Products: 78057, 78064, 78091, 78192
Storage Stability: Lentiviruses are shipped with dry ice. For long term storage, it is recommended to store the virus at -80°C. Avoid repeated freeze-thaw cycles. Titers can drop significantly with each freeze-thaw cycle.
Scientific Category: CRISPR